1 Major article

2	Effects of boosted mRNA and adenoviral-vectored vaccines on
3	immune responses to omicron BA.1 and BA.2 following the
4	heterologous CoronaVac/AZD1222 vaccination
5	Running title: Booster response to omicron subvariants
6	Nungruthai Suntronwong ¹ , Sitthichai Kanokudom ¹ , Chompoonut Auphimai ¹ , Suvichada
7	Assawakosri ¹ , Thanunrat Thongmee ¹ , Preeyaporn Vichaiwattana ¹ , Thaneeya Duangchinda ² ,
8	Warangkana Chantima ^{3,4} , Pattarakul Pakchotanon ² , Jira Chansaenroj ¹ , Jiratchaya Puenpa ¹ ,
9	Pornjarim Nilyanimit ¹ , Donchida Srimuan ¹ , Thaksaporn Thatsanatorn ¹ , Natthinee Sudhinaraset ¹ ,
10	Nasamon Wanlapakorn ¹ , Yong Poovorawan ^{1,5} *
11	
12	¹ Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
13	Bangkok 10330, Thailand
14	² Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic
15	Engineering and Biotechnology (BIOTEC), National Science and Development Agency,
16	NSTDA, Pathum Thani 12120, Thailand
17	³ Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine Siriraj Hospital,
18	Mahidol University, Bangkok 10700, Thailand
19	⁴ Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine
20	Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
21	⁵ The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand.

23	*Corresponding au	thor: Yong Poovorawan, M	D
----	-------------------	--------------------------	---

- 24 Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
- 25 Bangkok, Thailand. Email: yong.p@chula.ac.th
- 27 Abstract word count: 195
- 28 Main text word count: 3493

- ~ 4

46 Abstract

47	Background. The coronavirus 2019 omicron variant has surged rapidly and raises concerns
48	about immune evasion because it harbors mutations even in individuals with complete
49	vaccination. Here, we examine the capability of the booster vaccination to induce neutralizing
50	antibodies (NAbs) against omicron (BA.1 and BA.2) and T-cell responses.
51	Methods. A total of 167 participants primed with heterologous CoronaVac/AZD1222 were
52	enrolled to receive AZD1222, BNT162b2, or mRNA-1273 as a booster dose. Reactogenicity was
53	recorded. Binding antibody, neutralizing antibody (NAb) titers against omicron BA.1 and BA.2,
54	and total interferon gamma (IFN- γ) post-booster responses were measured.
55	Results. A substantial loss in neutralizing potency to omicron variant was found at 4 to 5 months
56	after receiving the heterologous CoronaVac/AZD1222. Following booster vaccination, a
57	significant increase in binding antibodies and neutralizing activities toward delta and omicron
58	variants was observed. Neutralization to omicron BA.1 and BA.2 were comparable, showing the
59	highest titers after boosted mRNA-1273 followed by BNT162b2 and AZD1222. Notably,
60	boosted individuals with mRNA vaccines could induce T cell response. Reactogenicity was mild
61	to moderate without serious adverse events.
62	Conclusions. Our findings highlight that the booster vaccination could overcome immunity
63	wanes and provide adequate NAbs coverage against omicron BA.1 and BA.2.
64	
65	Keywords: COVID-19; booster vaccine; omicron; mRNA vaccine; AZD1222
66	
67	
68	

69 INTRODUCTION

70 As of November 2021, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-71 2) omicron (B.1.1.529) variant quickly surged worldwide and raised concern about immune 72 evasion [1]. The omicron variant is characterized by many mutations in the spike protein. Among 73 these, fifteen mutations located on the receptor-binding domain (RBD), which are responsible for 74 interactions with the angiotensin-converting enzyme 2 (ACE2) receptor, and eight amino acid changes are found at the N-terminal domain (NTD) [2]. In a study of mutated RBD profiles, 75 various omicron mutations capable of escaping human neutralizing antibodies (NAbs) were 76 77 found to contain epitopes overlapping the ACE2 binding motif, indicating evasion of immunity 78 and reduction in vaccine effectiveness [3]. Furthermore, mutations in NTD related to partial 79 escape from the Nabs have been reported [4]. These findings are consistent with other clinical 80 data demonstrating that the emergence of the omicron variant has led to an increase in the risk of reinfection [5]. During the ongoing viral evolution, the omicron variant has been divided into 81 82 four subvariants, including BA.1, BA.1.1, BA.2, and BA.3 [6]. Among them, BA.1 surged 83 earlier and became the dominant subvariant circulating worldwide. However, the BA.2 84 subvariant has recently increased in multiple countries and appears to be more transmissible than 85 BA.1 [7]. Previous studies suggest that BA.1 and BA.2 are highly resistant to neutralization by 86 monoclonal antibody therapy and vaccine-induced immunity [8,9]. 87 Another concern is the waning immunity that occurs over time. A previous study

indicates that the IgG antibodies declined a consistent rate at six months after second dose of the
mRNA vaccination while neutralizing antibodies declined rapidly over the first three months
followed by a relatively slower decrease after that point [10]. A reduction in NAbs is related to
an increased risk of symptomatic SARS-CoV-2 infection and reduced vaccine effectiveness [11].

92 Moreover, omicron variants were poorly or not at all neutralized in the sera sampled five months 93 after completing the two-dose BNT162b2 or AZD1222 vaccination courses [12]. Due to the 94 emergence of omicron and waning immunity, a booster vaccination program has been 95 implemented in many countries [13,14]. Thus, data on boosting immunity against omicron 96 variant are needed. 97 Besides humoral immunity, cell-mediated immunity also plays an essential role in 98 limiting the SARS-CoV-2 infection [15] and reducing disease severity in acute coronavirus 2019 99 (COVID-19) patients [16]. The SARS-CoV-2-specific T-cells persist at least six months after 100 receiving the two-dose regimen of either mRNA or adenoviral-vectored vaccines, whereas the 101 levels of NAb severely declined [17]. Furthermore, SARS-CoV-2 specific T-cells induced by 102 vaccination or previous infection are highly cross-reactive with the omicron variant, and the 103 omicron-cross reactive T cells exhibiting the polyfunctional profiles were not significantly 104 different compared to ancestral strain and other SARS-CoV-2 variants [18]. These findings 105 indicate that a few mutations in the spike can minimally affected T-cell recognition. 106 Seven vaccines have now been authorized in Thailand: (1) inactivated CoronaVac, (2) 107 BBIBP-CorV, (3) adenoviral-vectored ChAdOx1-S/AZD1222, (4) Ad26.COV2.S, (5) mRNA-108 based BNT162b2, (6) mRNA-1273, and (7) protein-based NVX-CoV2373 vaccines [19]. 109 However, the vaccine effectiveness and capability of inducing immune responses differ with 110 different types of vaccines and are affected by emerging variants [20]. Our previous study 111 indicated that mRNA vaccine- or AZD1222-boosted individuals after a two-dose CoronaVac 112 course elicited a higher immune response than in those receiving boosted inactivated vaccines 113 [21]. In the COV-BOOST trial, the heterologous boost after either two-dose of AZD1222 or 114 BNT162b2 prime showed an increased humoral and cell-mediated immune response compared

115 to homologous booster vaccination, although the reactogenicity was increasing in some 116 heterologous boosted combination [22]. However, information about the effects of booster 117 vaccinations on safety and immune responses against omicron variants following heterologous 118 primed has been limited. 119 Due to the limited vaccine supply, Thailand has administered the heterologous 120 CoronaVac followed by AZD1222 vaccination as an alternative regimen for combatting the delta 121 variant. This regimen could induce a higher immune response than the homologous CoronaVac 122 regimen [23]. However, the antibodies wane over time, and the emergence of the omicron 123 variant has raised concerns about booster vaccinations. In this study, the safety and capability of 124 inducing NAbs against the omicron variant (BA.1 and BA.2 subvariants) and T-cell responses 125 after receiving AZD1222, BNT162b2, or mRNA-1273 as a booster dose in individuals who were 126 previously vaccinated with the heterologous CoronaVac/AZD1222 regimen were evaluated. 127 These findings support the policymakers' choices about which booster vaccines to use in the 128 population to overcome waning immunity and prevent breakthrough infections during the recent 129 emergence of the SAR-CoV-2 variants. 130 131 **MATERIALS AND METHODS** 132 Study design

In a cohort study, 167 individuals who had received CoronaVac/AZD1222 vaccination at
least 4 to 5 months earlier and with no history of SARS-CoV-2 infection were enrolled. The
participants were offered immunization with one of three approved vaccines, including
AZD1222, BNT162b2, or mRNA-1273 vaccines. The cohort study started between November
30, 2021 and January 24, 2022. The participants received adverse events (AEs) documents to

138	record reactogenicity within seven days after receiving their booster dose. Blood samples were
139	collected before vaccination (day 0) and on days 14 and 28 after booster vaccination. The study
140	protocol was reviewed and approved by the Institutional Review Board of the Faculty of
141	Medicine, Chulalongkorn University (IRB numbers 871/64) and performed under the
142	Declaration of Helsinki and Good Clinical Practice principles. This study was registered with the
143	Thai Clinical Trials Registry (TCTR20211120002). All participants signed a written consent
144	before being enrolled in this study.
145	Study vaccines
146	The study vaccines used as booster doses included AZD1222 (AstraZeneca, Oxford, UK)
147	[24], BNT162b2 (Pfizer-BioNTech Inc., New York City, NY) [25], and mRNA-1273 (Moderna
148	Inc., Cambridge, MA) [26]. All vaccines were designed using the SARS-CoV-2 spike of
149	ancestral strain as a template.
150	Measurement binding antibody and neutralizing activity using ELISA- based assay
151	All some some las some lasti BDD L C and artisme laster i (Al) L C social
	All sera samples measured anti-RBD IgG and anti-nucleocapsid (N) IgG using
152	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG
152	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG
152 153	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG was expressed as a binding antibody unit (BAU/mL), and a value \geq 7.1 was considered positive.
152 153 154	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG was expressed as a binding antibody unit (BAU/mL), and a value \geq 7.1 was considered positive. Anti-N IgG reported as S/C ratio (optical density [OD] sample divided by calibrator) with a
152 153 154 155	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG was expressed as a binding antibody unit (BAU/mL), and a value \geq 7.1 was considered positive. Anti-N IgG reported as S/C ratio (optical density [OD] sample divided by calibrator) with a value \geq 1.4 was considered positive. In addition, a subset of samples was randomly selected to
152 153 154 155 156	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG was expressed as a binding antibody unit (BAU/mL), and a value \geq 7.1 was considered positive. Anti-N IgG reported as S/C ratio (optical density [OD] sample divided by calibrator) with a value \geq 1.4 was considered positive. In addition, a subset of samples was randomly selected to perform surrogate virus neutralization assay (sVNT) against delta and omicron variants using a
152 153 154 155 156 157	enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG was expressed as a binding antibody unit (BAU/mL), and a value \geq 7.1 was considered positive. Anti-N IgG reported as S/C ratio (optical density [OD] sample divided by calibrator) with a value \geq 1.4 was considered positive. In addition, a subset of samples was randomly selected to perform surrogate virus neutralization assay (sVNT) against delta and omicron variants using a cPass TM SAR-CoV-2 neutralizing antibody detection kit (GenScript Biotech, Piscataway, NJ) as

161 of detection was set as 0% inhibition.

162 Focus Reduction Neutralization test (FRNT50)

163	Live SARS-CoV-2 neutralizing antibody titers in a subset of serum samples were
164	determined using a 50% focus reduction neutralization test (FRNT50) against omicron BA.1
165	(accession number: EPI_ISL_8547017) and BA.2 (EPI_ISL_11698090) subvariants. Briefly,
166	heat-inactivated sera were used to prepare serial dilutions starting from 1:10 to 1:7,290 and
167	incubated with live virus for 1 h at 37 °C. The virus-sera mixtures were transferred to
168	monolayers of Vero cells in a 96-well plate and incubated for 2 h. Foci development evaluation
169	and infected cell counting were performed as previously described [27]. The focus reduction
170	percentage for an individual sample was calculated, and the half-maximal inhibitory
171	concentration (IC ₅₀) was evaluated using PROBIT software. If no neutralization was observed,
172	the FRNT50 was set as 10, which is one dilution step below the lower limit of detection (dilution
173	1:20).
174	Quantification of interferon-gamma response
175	The SARS-CoV-2-specific T-cell response was evaluated by using a commercially
176	available IFN- γ release assay in whole blood according to the manufacturer's instructions
177	(QuantiFERON, Qiagen, Hilden, Germany). Heparinized whole blood was incubated with
178	different antigens, including negative (Nil), positive (Mitogen) and two different SARS-CoV-2
170	

antigens (Ag1 and Ag2). The Ag1 tube was coated with S1subunit (RBD) peptides with CD4+

stimulation, and Ag2 contained S1+S2 peptides for CD4+ and CD8+ stimulation. After

stimulation, total IFN-γ production was measured as previously described [23]. The results were

182 calculated from a standard curve and expressed as IU/mL after subtraction of the Nil control. The

total IFN-γ with a value ≥ 0.15 IU/mL and $\ge 25\%$ of Nil were considered a positive response against SARS-CoV-2.

185 Statistical analyses

186 Baseline characteristics were expressed as number or percentage and median with 187 interquartile ranges (IQRs). The levels of binding antibody and NAbs were presented as 188 geometric mean titers (GMT). A comparison of log-transformed data was determine using one-189 way analysis of variance (ANOVA) with Bonferroni adjustment. The Kruskal-Wallis test with 190 Dunn's post hoc correction and Mann-Whitney test were used for unpaired samples, while the 191 Friedman and Wilcoxon signed-rank tests were used for paired samples in cases in which data 192 were not normally distributed. Spearman's R was used to determine the correlation. A P-value < 193 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 194 v23.0 (IBM Corp, Armonk, NY). Figures were generated using GraphPad Prism v9.0 (GraphPad, 195 San Diego, CA) and R version 3.6.0 (R Foundation, Vienna, Austria). Details of statistical 196 analysis for each experiment are described in the figure legends. 197

198 **RESULTS**

199 Study participants

A total of 167 vaccinated individuals who received heterologous CoronaVac/AZD1222 were enrolled to receive AZD1222 (n = 60), BNT162b2 (n = 55), and mRNA-1273 (n = 52) with a booster interval ranging from 4 to 5 months post-second dose (Figure 1A). Overall, participants included 83 (49.7%) women and 84 (50.3%) men with ages ranging from 19 to 64 years. The mean age of participants who received AZD1222 was 41.2 years (IQR: 38.5–43.9), BNT162b2 39.0 years (IQR: 36.4–41.6), and mRNA-1273 43.9 years (IQR:40.9–46.8) as booster doses were

not significantly different (Table 1). Additionally, no statistically significant differences were
observed in the time intervals between the first and the second doses for any group. However, the
median interval between the second and third dose in AZD1222 (125 days, IQR: 118–134.5) was
slightly shorter (but not statistically significant) than BNT162b2 (130 days, IQR: 110–141) and
mRNA-1273 (131 days, IQR:102.3–133).

211 Increase binding antibodies level after boost

212 Waning immunity against SARS-CoV-2 in heterologous CoronaVac/AZD1222 primed 213 individuals was determined. The anti-RBD IgG at one month (n = 35) as reported in a previous 214 study [23] was individually compared to 4 to 5 months after the second dose (baseline in this 215 cohort) as shown in Supplementary Figure 1. As expected, a significant drop (5.9-fold) in anti-216 RBD IgG within 4 to 5 months (109.6 BAU/mL) occurred compared to one-month post-second 217 dose (652.1 BAU/mL; p < 0.001). This result indicates a decline in immunity over time in 218 vaccinated individuals who received heterologous CoronaVac/AZD1222. Following booster 219 vaccination, the anti-RBD IgG significantly increased and peaked at day 14 for all vaccines (p < p220 0.001) as shown in Figure 1B. Comparing pre- and post-boost, mRNA-1273-boosted individuals 221 achieved an anti-RBD IgG with a 23-fold increase (126.9 versus 2921 BAU/mL) and showed a 222 higher level than the other vaccine groups, while BNT162b2 and AZD1222 groups were induced 223 by 15.8-fold (152.1 versus 2404 BAU/mL) and 2.5-fold (142 versus 360.8 BAU/mL) higher 224 than baseline. Furthermore, anti-RBD IgG levels correlated negatively with age in boosted 225 mRNA-1273 individuals although these differences were not significant. On the contrary, the 226 age-related trend was not found in AZD1222- or BNT162b2-boosted individuals (Figure 1C). 227 Most boosted individuals were seronegative for anti-N IgG, indicating no SARS-CoV-2

exposure during the study period (Figure 1D). Although one participant had an anti-N IgG levelabove the cut-off, the anti-RBD IgG level was comparable with other participants at baseline,

- suggesting the anti-N IgG may be induced by CoronaVac prime vaccination.
- 231

Neutralizing activity to delta and omicron measured using sVNT

232 Neutralizing activity to the delta and omicron variants was measured in sera at baseline 233 and 28 days after post-boost using the surrogate virus neutralization test. All boosted individuals 234 could restore neutralizing activity to delta by more than 90% (Figure 2A). Although baseline 235 neutralizing activity to omicron declined at 4 to 5 months after the second dose, a 20% (6/30), 236 83% (25/30), and 90% (27/30) of individuals boosted with AZD1222, BNT162b2, and mRNA-237 1273, respectively, were detected to possess omicron variant neutralizing potential (Figure 2B). 238 By comparison, it was noted that individuals boosted with mRNA vaccines demonstrated a higher level of neutralizing activity than those boosted with AZD1222. The median of 239 240 neutralizing activity to omicron was 10.1% for AZD1222, 55.9% for BNT162b2, and 78.2% for 241 mRNA-1273 after booster vaccination. Although neutralizing activity against omicron was 242 significantly lower than that against the delta variant, most individuals have detected the 243 neutralizing activity against omicron after receiving booster mRNA vaccines (Figure 2C).

244 Comparison of neutralizing antibody titers to omicron BA.1 and BA.2

The functional NAb titers against omicron BA.1 and BA.2 were quantified using a live
virus neutralization test (FRNT50). At baseline, 80% (24/30) and 43% (13/30) of vaccinated
individuals with heterologous CoronaVac/AZD1222 had NAbs to omicron BA.1 and BA.2,
respectively, which dropped below detectable levels (Figure 3). After 28 days post-boost, NAb

.

~

10.01.151.0

249	titers against omicron BA.1 were 40.34, 171.0, and 271.6 after AZD1222, BNT162b2, and
250	mRNA-1273 boosters, respectively, reflecting a 3.16-, 9.91- and 24.78-fold increase compared to
251	baseline, respectively (Figure 3A). The NAb titers against omicron BA.2 in AZD1222,
252	BNT162b2, and mRNA-1273 groups were 59.27, 130.7, and 235.3, respectively, which reached
253	a 2.43-, 4.63- and 19.67-fold induction relative to baseline, respectively (Figure 3B). This
254	finding indicates that the omicron variant is more susceptible to neutralization by sera from
255	individuals boosted with mRNA vaccines (BNT162b2 and mRNA-1273) than those boosted with
256	AZD1222. Overall, the NAb titers to BA.1 and BA.2 were comparable. By comparison, the NAb
257	titer to BA.2 was 1.47-fold higher in the AZD1222 group and 1.31- and 1.15- fold lower in the
258	BNT162b2 and mRNA-1273 groups, respectively, compared to BA.1 (Figure 3C). Moreover, it
259	was shown that anti-RBD IgG and sVNT to omicron correlated well with the NAb titers against
260	omicron BA.1. and BA.2 as measured using the live virus neutralization test (FRNT50) as shown
261	in Supplementary Figure 2.

262 Total interferon-gamma response

.

- . .

263 Besides the neutralizing antibodies, the T cell response were assessed by measuring total 264 IFN-y responses in whole blood from AZD1222-, BNT162b2-, and mRNA-1273-boosted 265 individuals after S1 (RBD) peptides for CD4+ stimulation or Ag1 (Figure 4A) and S1+S2 266 peptides for CD4+ and CD8+ stimulation or Ag2 (Figure 4B). At baseline, 47% (43/90) and 267 57.7% (52/90) of participants could elicit IFN-y responses after Ag1 and Ag2 stimulation after 4 268 to 5 months post-second dose. Following booster vaccination, IFN-y levels significantly 269 increased at 14 days after receiving BNT162b2 and mRNA-1273 as booster doses. Notably, 270 90%–97% of individuals boosted with BNT162b2 and mRNA-1273 could induce IFN-y

responses after stimulation with the spike protein of the ancestral strain. On the contrary, no
difference in IFN-γ response in those boosted with AZD1222 compared to baseline was found.
This result indicates that individuals boosted with BNT162b2 and mRNA-1273 vaccines could
induce a T-cell response, which elicits a higher level of IFN-γ response, but this process was not
observed in those boosted with the AZD1222 vaccine.

276 Reactogenicity after booster vaccination

Local and systemic reactogenicity were self-reported within seven days after booster 277 278 vaccination. A high frequency of adverse events (AEs) was observed within 2 to 3 days 279 following the booster dose and were predominantly mild to moderate (Supplementary Figure 3). 280 Boosted individuals with BNT162b2 and mRNA-1273 vaccines reported greater local and 281 systemic reactogenicity than those receiving the AZD1222 vaccine. Overall, the most common 282 AEs observed in boosted individuals were injection site pain, redness, and swelling indicating 283 local AEs, while myalgia headache and chills were frequently reported as systemic AEs (Figure 284 5). However, no serious AEs were reported.

285

286 **DISCUSSION**

This study demonstrated the NAb response against omicron BA.1 and BA.2 subvariants and T-cell responses after boosting with AZD1222, BNT162b2, and mRNA-1273 in vaccinated individuals who had received heterologous CoronaVac/AZD1222 prime. It was found that a booster vaccination could restore the binding antibody response and induce NAb titers against omicron BA.1 and BA.2. Of note, our findings indicate that individuals boosted with mRNA-1273 and BNT162b2 vaccines could induce humoral and T-cell responses higher than those boosted with AZD1222. Although mRNA vaccines showed a higher frequency of AEs than

AZD1222 vaccine, the reactogenicity was in acceptable ranges, indicating a good safety profilesafter booster vaccination.

296 It was found that individuals who received the heterologous CoronaVac/AZD1222 297 vaccination exhibited a 5.9-fold reduction in binding antibody and less detectable NAbs to 298 omicron variants after 4 to 5 months post-second dose, indicating waning of vaccine-induced 299 immunity [10]. It has been well established that booster vaccinations could overcome the waning 300 immunity [14,21,22,28]. Rapid elevation in binding antibodies after boosting with mRNA and 301 adenoviral-vectored vaccines were found. Similar results have been reported after receiving 302 either a viral-vectored or an mRNA vaccine as a third dose, indicating that it was sufficient to 303 recall the memory B-cells [28]. Typically, vaccine-induce immunity negatively correlates with 304 age and drops significantly around the ages of 80 years [29]. However, those age-related trends 305 were not found in this study, which might because most participants were less than 60 years old. 306 Neutralizing antibody titers is a highly predict the immune protection against SARS-307 CoV-2 infection. Higher levels of NAbs correlated with a reduced risk of infection and severe 308 disease [11]. Our study found a substantial loss of NAb titers against omicron variants at pre-309 booster vaccination. This effect might be related to harboring of mutations concentrated around 310 the RBD [3]. However, the NAb titers against omicron were retained upon booster vaccination 311 even though the current vaccines composition was based on the ancestral strain. Consistent 312 results were observed after receiving mRNA vaccine following either homologous inactivated, 313 adenoviral-vectored, or mRNA-based vaccines prime [14,21,22,30]. Although the low number of 314 omicron-neutralizing memory B-cells produced after two-doses of mRNA vaccination has 315 previously been reported, their coverages were improved through affinity maturation over time 316 and might be sufficient to expand the coverage of neutralization against SARS-CoV-2 variants

317 after receiving a booster dose [31]. Furthermore, a reduced neutralizing activity against omicron 318 compared to delta variant was found. Similar results were found concerning neutralizing activity to omicron, which was reduced by 6- to 23-fold lower than delta after booster vaccination [12]. 319 320 With the surge of omicron BA.1 and BA.2 subvariants, a substantial loss of NAbs to 321 omicron BA.1 and BA.2 subvariants was observed in vaccinated individuals with two doses of 322 mRNA vaccine and patients who previously were infected with wild-type SARS-CoV-2 [32]. 323 Furthermore, a study of the neutralizing antibody of omicron subvariants indicated that a 23-fold 324 reduction for BA.1 and a 27-fold reduction for BA.2 was observed compared to wild -type in 325 vaccinated individuals who received the two doses of BNT162b2 vaccine [30]. Our findings 326 indicate that booster vaccination with mRNA and adenoviral-vectored vaccines could increase 327 the neutralizing antibody titers and coverage against omicron BA.1 and BA.2. Consistent results 328 showed an improvement in neutralization sensitivity against BA.1 and BA.2 after individuals 329 were boosted with the mRNA vaccine [30,33]. Although both subvariants shared several 330 common amino acid changes, the unique mutations found in each subvariant might affect the 331 differences in neutralization potency [32]. However, it was found that the NAb titer of BA.1 and 332 BA.2 were comparable and trended higher in the adenoviral-vectored booster and lower in 333 mRNA vaccines. A recent study showed a 1.4-fold lower neutralizing antibody titer to BA.2 334 compared to BA.1 [30]. This result indicates that booster vaccination is a useful strategy for 335 controlling the omicron BA.1 and BA.2 pandemic. 336 A study of T-cell responses targeting the omicron spike protein suggested that no 337 differences in T-cell profiles and cytokine production between omicron and wild type were 338 found [17]. This finding indicates cross-recognition of T-cells was minimally affected by

mutations in the omicron spike protein [18,34]. A current study showed that individuals boosted

340 with the mRNA vaccine could induce T-cell activity in whole blood. Cross-recognition of 341 different SARS-CoV-2 variants by T-cells was maintained after being boosted with mRNA 342 vaccine has been reported [17,35]. On the contrary, our result showed that individuals boosted 343 with AZD1222 following heterologous CoronaVac/AZD1222 appeared to abolish T-cell 344 responses. 345 Study limitations include the detection limits of the surrogate virus neutralization assay. 346 Most boosted individuals elicited an elevation in antibody level that was higher than the upper 347 limit of detection; thus, this method may not have provided the actual neutralizing antibody level 348 in case of a robust immune response. Furthermore, the effect of omicron peptide stimulation on 349 T-cell response was not examined. However, van Kessel et al. showed that no difference in 350 cytokine production was observed upon stimulation with S-peptide pools derived from the 351 ancestral strain and omicron variants [17]. Further studies are required to define long-term 352 immunity and durability of immune responses against SARS-CoV-2 variants, particularly 353 omicron subvariants, after administration of booster vaccinations. 354 In conclusion, these findings indicate that booster vaccination could retain the level of 355 anti-RBD IgG and improved the neutralizing activity against delta and omicron variants. Of note, 356 a booster dose could induce neutralizing antibody titers to omicron BA.1 comparable to BA.2. 357 Furthermore, individuals boosted with mRNA vaccines could induce IFN-γ responses higher 358 than those boosted with AZD1222. Hence, giving mRNA vaccines as the booster dose could 359 improve humoral and T-cell responses and induce neutralization coverage against omicron 360 subvariants. 361

363 **Conflicts of Interest:** All authors have declared no competing interests.

364

365	Funding Statement: This work was supported by the National Research Council of Thailand,				
366	the Health Systems Research Institute, the Center of Excellence in Clinical Virology of				
367	Chulalongkorn University, and King Chulalongkorn Memorial Hospital. National Center for				
368	Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613). Nungruthai				
369	Suntronwong reports that financial support was also provided by the Second Century Fund				
370	Fellowship of Chulalongkorn University.				
371					
372	Acknowledgements: We would like to thank all the staffs of the Center of Excellence in Clinical				
373	Virology and all the participants for helping and supporting in this project. We also appreciate				
374	the Ministry of Public Health, Chulabhorn Royal Academy and Zullig pharma for providing				
375	the vaccines for this study.				
376					
377	Corresponding author contact information				
378	1. Prof. Dr. Yong Poovorawan, Center of Excellence in Clinical Virology, Department of				
379	Pediatrics, Faculty of Medicine, Chulalongkorn University. Bangkok, 10330 Thailand.				

380 Email: Yong.P@chula.ac.th

381 REFERENCE

382	1.	Viana R, Moyo S.	Amoako DG, et	al. Rapid e	pidemic ex	pansion of	f the SARS-CoV-2	2
-----	----	------------------	---------------	-------------	------------	------------	------------------	---

- 383 Omicron variant in southern Africa. *Nature* 2022; 603:679-86.
- 3842.Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and
- immune escape. *Nat Rev Microbiol* 2021; 19:409-24.
- 386 3. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2
 387 neutralizing antibodies. *Nature* 2022; 602:657-63.
- Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron
 variant of SARS-CoV-2. *Nature* 2022; 602:676-81.
- 390 5. Pulliam JR, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2

reinfection associated with emergence of Omicron in South Africa. *Science* 2022;eabn4947.

- 393 6. Kumar S, Karuppanan K, Subramaniam G. Omicron (BA. 1) and Sub-Variants (BA. 1,
- BA. 2 and BA. 3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative
- 395 Sequence and Structural-based Computational Assessment [preprint]. *bioRxiv* 2022. doi:
- **396** 10.1101/2022.02.11.480029.
- 397 7. GISAID. Overview of Variants/Mutations. Available at: https://covariants.org/per-variant
 398 [Internet]. Accessed 16 April 2022.
- 399 8. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral
- 400 Drugs against Covid-19 Omicron Variant. *N Engl J Med* 2022; 386:995-8
- 401 9. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral Agents against the
- 402 SARS-CoV-2 Omicron Subvariant BA. 2. *N Engl J Med* 2022; 386:1475-7.

403	10.	Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2
404		Covid-19 vaccine over 6 months. N Engl J Med 2021; 385:e84.
405	11.	Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
406		predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med
407		2021; 27:1205-11.
408	12.	Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to
409		antibody neutralization. Nature 2022; 602:671-75.
410	13.	Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster
411		against Covid-19 in Israel. N Engl J Med 2021; 385:1393-1400.
412	14.	Munro AP, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19
413		vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
414		BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,
415		phase 2 trial. Lancet 2021; 398:2258-76.
416	15.	McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
417		rhesus macaques. Nature 2021; 590:630-34.
418	16.	Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to
419		SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell
420		2020; 183:996-1012.
421	17.	GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS CoV-2 Omicron-
422		reactive T-and B cell responses in COVID-19 vaccine recipients. Sci Immunol 2022;
423		7:eabo2202.
424	18.	Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-

425 recognize Omicron. *Nature* 2022; 603:488-92.

426	19.	Snyder J, Root-Wiley M. 7 vaccines Apprved for Use in Thailand [Internet]. Available at:				
427		https://covid19.trackvaccines.org/country/thailand/. Accessed 16 April 2022.				
428	20.	Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the				
429		omicron (B. 1.1. 529) variant. N Engl J Med 2022; 386;1532-46.				
430	21.	Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing Activities against the				
431		Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses				
432		of CoronaVac Vaccination. J Infect Dis 2022; jiac092. doi: 10.1093/infdis/jiac092.				
433	22.	Liu X, Munro AP, Feng S, et al. Persistence of immunogenicity after seven COVID-19				
434		vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or				
435		BNT162b2 in the UK: three month analyses of the COV-BOOST trial. J Infect 2022;				
436		S0163-4453(22)00200-6. doi: 10.1016/j.jinf.2022.04.018.				
437	23.	Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and				
438		immunogenicity of heterologous and homologous inactivated and adenoviral-vectored				
439		COVID-19 vaccines in healthy adults. Hum Vaccin Immunother 2022; 18:2029111.				
440	24.	Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1				
441		nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,				
442		randomised controlled trial. Lancet 2020; 396:467-78.				
443	25.	US Food and Drug Administration. Package Insert – Comrinaty [Internet]. Available at:				
444		https://www.fda.gov/media/151707/download. Accessed 16 April 2022.				
445	26.	US Food and Drug Administration. Fact sheet for healthcare providers administering				
446		vaccine-the moderna covid-19 vaccine [Internet]. Available at:				
447		https://www.fda.gov/media/144637/download. Accessed 16 April 2022.				

- 448 27. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B. 1.1.
- 449 7 variant by convalescent and vaccine sera. *Cell* 2021; 184:2201-11.
- 450 28. Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third
- 451 dose of inactivated SARS-CoV-2 vaccine. *Cell Discov* 2022; 8:10.
- 452 29. Collier DA, Ferreira IA, Kotagiri P, et al. Age-related immune response heterogeneity to
- 453 SARS-CoV-2 vaccine BNT162b2. *Nature* 2021; 596:417-22.
- 454 30. Yu J, Collier A-rY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1
 455 and BA. 2 variants. *N Engl J Med* 2022; 386:1579-80.
- 456 31. Kotaki R, Adachi Y, Moriyama S, et al. SARS-CoV-2 Omicron-neutralizing memory B-
- 457 cells are elicited by two doses of BNT162b2 mRNA vaccine. *Sci Immunol* 2022;
 458 7:eabn8590.
- 459 32. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron
 460 sublineages. *Nature* 2022; 604:553-6.
- 461 33. Bowen JE, Sprouse KR, Walls AC, et al. Omicron BA. 1 and BA. 2 neutralizing activity
- 462 elicited by a comprehensive panel of human vaccines [preprint]. *bioRxiv* 2022. doi:
- **463** 10.1101/2022.03.15.484542.
- 464 34. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize
 465 the Omicron variant. *Nat Med* 2022; 28:472-6.
- 466 35. Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 Omicron
- 467 variant is preserved in most but not all prior infected and vaccinated individuals
- 468 [preprint]. *medRxiv* 2022. doi: 10.1101/2022.01.04.21268586.
- 469
- 470


Characteristics	Total	AZD1222	BNT162b2	mRNA-1273	p-value	
	(n=167)	(<i>n</i> = 60)	(<i>n</i> = 55)	(n = 52)		
Sex (<i>n</i> , %)						
female	83 (49.7%)	37 (61.7%)	26 (47.3%)	20 (38.5%)	<i>p</i> =0.045 ^a	
male	84 (50.3%)	23 (38.3%)	29 (52.7%)	32 (61.5%)		
Age in years (mean, IQR)	41.3 (35-48)	41.2 (38.5-43.9)	39.0 (36.4-	43.9 (40.9-46.8)	$p = 0.052^{b}$	
			41.6)			
Interval between 1^{st} and 2^{nd}	27 (21-28)	24 (21-28)	27 (21-28)	27 (24.3-28)	$p = 0.332^{c}$	
dose (median, IQR)						
Interval between 2 nd and 3 rd	130 (110-135)	125 (118-134.5)	130 (110-141)	131 (102.3-133)	$p = 0.281^{c}$	
dose (median, IQR)						

471 **Table 1:** Characteristics of participants in the study.

472 ^a represents the association in sex distributed between groups using Chi-square test. ^b represents the

473 mean different in age between groups using one-way ANOVA. ^c represents the comparison in dosing


474 interval between groups using Kruskal-Wallis H test.




477 Figure 1: Study design and measurement of severe acute respiratory syndrome coronavirus 478 2 (SARS-CoV-2)-specific binding antibody responses. Schematic depicting a total of 167 479 vaccinated individuals with heterologous CoronaVac/AZD1222 enrolled in cohort study. They 480 were assigned to receive booster vaccines, either AZD1222 (n = 60), BNT162b2 (n = 55), or 481 mRNA-1273 (n = 52) and blood samples were collected on days 0, 14, and 28 after booster 482 vaccination (Panel A). The anti-receptor binding domain (RBD) IgG (BAU/mL) in sera from boosted individuals with different vaccines, AZD1222 (purple), BNT162b2 (green) and mRNA-483 1273 (yellow), were compared. (Panel B). Scatter plots shows simple linear fit between anti-484 485 RBD IgG and age with Spearman's R correlation coefficients and P-values (Panel C). Anti-N 486 IgG was measured at different time points (Panel D). Error bars in Panels B and D indicate the geometric mean titers (GMT) and median, respectively. The cut-off values were represented by 487


488 dotted lines.


489







medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274294; this version posted April 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







518 Figure 4: Comparison of total IFN-y -releasing T-cell responses to SARS-CoV-2 antigens. 519 Serum samples from vaccinated individuals receiving heterologous CoronaVac/AZD1222 520 followed by a third booster with AZD1222 (n = 30, purple), BNT162b2 (n = 30, green), or 521 mRNA-1273 (n = 30, yellow) were stimulated by (A) Ag1, which is a CD4+ epitope derived 522 from RBD, minus negative control (Nil), and (B) Ag2, which is CD4+ and CD8+ epitopes derived from S1 and S2 subunits, minus negative control (Nil). Levels of IFN-y above cutoff 523 values (0.15 IU/mL and > 25% of Nil) indicate a reactive response. Horizontal bars indicate the 524 525 median. The cut-off values were represented by horizontal dotted line. Statistical analysis was 526 done using Wilcoxon signed rank test (two-tailed). ns indicates no significant difference; **, p < 0.01; ***, p < 0.001. 527



529

530 Figure 5: Forest plot showed the risk difference with 95% confidence intervals od adverse

531 events (AEs) after the booster dose. The proportion of participants with any grade of solicited

- 532 Aes after the third booster were compared between (Panel A) AZD1222 versus BNT162b2
- vaccine (Panel B) AZD1222 versus mRNA-1273, and (Panel C) BNT162b2 versus mRNA-

534 1273.